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Abstract 
Background: Constitutive MET signaling promotes invasiveness in most primary and recurrent GBM. However, 
deployment of available MET-targeting agents is confounded by lack of effective biomarkers for selecting suitable 
patients for treatment. Because endogenous HGF overexpression often causes autocrine MET activation, and also 
indicates sensitivity to MET inhibitors, we investigated whether it drives the expression of distinct genes which could 
serve as a signature indicating vulnerability to MET-targeted therapy in GBM.
Methods: Interrogation of genomic data from TCGA GBM (Student’s t test, GBM patients with high and low HGF 
expression, p ≤ 0.00001) referenced against patient-derived xenograft (PDX) models (Student’s t test, sensitive vs. 
insensitive models, p ≤ 0.005) was used to identify the HGF-dependent signature. Genomic analysis of GBM xeno-
graft models using both human and mouse gene expression microarrays (Student’s t test, treated vs. vehicle tumors, 
p ≤ 0.01) were performed to elucidate the tumor and microenvironment cross talk. A PDX model with EGFRamp was 
tested for MET activation as a mechanism of erlotinib resistance.
Results: We identified a group of 20 genes highly associated with HGF overexpression in GBM and were up- or 
down-regulated only in tumors sensitive to MET inhibitor. The MET inhibitors regulate tumor (human) and host 
(mouse) cells within the tumor via distinct molecular processes, but overall impede tumor growth by inhibiting 
cell cycle progression. EGFRamp tumors undergo erlotinib resistance responded to a combination of MET and EGFR 
inhibitors.
Conclusions: Combining TCGA primary tumor datasets (human) and xenograft tumor model datasets (human tumor 
grown in mice) using therapeutic efficacy as an endpoint may serve as a useful approach to discover and develop 
molecular signatures as therapeutic biomarkers for targeted therapy. The HGF dependent signature may serve as a 
candidate predictive signature for patient enrollment in clinical trials using MET inhibitors. Human and mouse micro-
arrays maybe used to dissect the tumor-host interactions. Targeting MET in EGFRamp GBM may delay the acquired 
resistance developed during treatment with erlotinib.
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Background
Glioblastoma (GBM) exhibits infiltrative tumor growth, 
a feature which is a prominent cause of mortality [1, 2]. 
Despite progress in understanding the molecular mech-
anisms of GBM invasiveness, there remains a lack of 
effective therapeutic approaches. MET activation leads 
to RTK/RAS/PI3 K pathway signaling [3–5] and is asso-
ciated with a GBM mesenchymal phenotype, which is 
more invasive and associated with shorter patient sur-
vival [5, 6]. These traits of GBM argue for the use of drugs 
directed against MET for treating certain GBM patients.
The epidermal growth factor receptor (EGFR) is fre-
quently amplified, overexpressed, and/or variantly 
spliced (EGFRvIII) in GBM [4], therefore is being evalu-
ated extensively as a promising target for treating GBM. 
However, the effects of EGFR-targeted therapy remains 
inclusive [7]. Although at preclinical level EGFR inhibi-
tor alone or in combination with radiation therapy both 
showed efficacy in treating GBM tumors, clinically, 
no overall benefit has been observed in GBM patients 
treated with EGFR inhibitors [8, 9]. The major challenge 
of EGFR- targeted therapy is the inherent and acquired 
resistance, including the acquisition of secondary EGFR 
point mutations, co-activation of other receptor tyros-
ine kinases, such as IGFR1, MET, PDGFα/β, and uPAR 
[10]. Intriguingly, EGFRvIII is cross-activated by MET 
in GBM models [11] and MET inhibitors synergize with 
EGFR inhibitors against GBM xenografts harboring both 
EGFRvIII mutation and PTEN deletion [12]. Other con-
cerns also include the low efficiency of EGFR inhibitor in 
penetrating blood brain barrier [7].
The Cancer Genome Atlas Network (TCGA) enables 
discovery of signatures for the molecular classification of 
GBM [6] as well as discerning distinct, aberrantly activated 
signaling pathways [4]. Recent work by Brennan et al. dem-
onstrated that systematic genomic analyses with detailed 
clinical annotation, including treatment and survival out-
comes, can be used to discover genomic-based predictive 
and therapeutic biomarkers [13]. Strategies to establish 
genomic signatures which predict therapeutic response 
at a preclinical level, if validated in follow-up patient stud-
ies, offer to improve patient selection for clinical trials and 
accelerate the development of targeted therapy and help 
realize the promise of personalized medicine.
Previously, we demonstrated that Hepatocyte growth 
factor (HGF)-autocrine activation is a strong molecu-
lar feature that predicts sensitivity to MET inhibitors 
in GBM [14]. Because GBM is a heterogeneous disease 
in which drug response can be influenced by different 
mechanisms, the expression of a single gene (i.e., HGF 
expression) was not expected to fully account for sensi-
tivity to the drug; recent results from clinical trials have 
shown that total MET expression levels do not indicate 
responsiveness to MET inhibitors [15]. In this study, we 
attempted to extend our findings to a molecular signature 
that can be used as a biomarker to indicate sensitivity to 
MET inhibitors. Further, using both human and mouse 
gene expression microarrays, we studied how the micro-
environment may respond to MET inhibition. Finally, we 
show that in GBM with EGFR amplification (EGFRamp), 
long-term exposure to erlotinib induces adaptive tumor 
growth that involves MET pathway activation, support-
ing the use of a combination of both inhibitors to more 
effectively control GBM progression.
Methods
Cell culture and compounds
DBM2, U251M2, U87M2 are subclones of DBTRG-MG, 
U251MG, and U87MG cells as described previously 
[16]. U118 and SF295 were from NCI-60 [14]. U87M2 
and DBM2 cells were transfected with pCLPCX-MCS1 
plasmid containing AP-1 transcriptional factor and 
firefly luciferase (Vertex Pharmaceuticals). The KCI-
10-40X1 xenograft tumor line was generated from the 
primary tumor of a GBM patient upon surgical removal 
at Karmanos Cancer Institute. G116 and G91 are patient- 
derived xenograft (PDX) models provided by the Mayo 
Clinic. All studies involving human subjects and human 
tissues were approved by the IRB of Van Andel Research 
Institute. V-4084 is a MET inhibitor provided by Vertex 
Pharmaceutics and erlotinib was purchased through L C 
Laboratories (Woburn, MA).
Kinase inhibitory assay
The inhibitory activity of V-4084 against 15 kinases was 
determined using the residual kinase activity of MET 
using a radiometric assay as described in Additional 
file 1: Supplementary Methods.
3D cell invasion assay
U87MG cells were first grown in 1  % soft agar (Sigma) 
for 7  days to form spheroids. Each spheroid was then 
selected and placed onto Matrigel in a well to attach 
overnight (day 0), followed by treatment with DMSO or 
serially diluted compounds. Images were taken after an 
additional 3  days under a light microscope. Triplicates 
were tested for each concentration.
HGF induced proliferation assay and urokinase activity 
assay and Western Blot
These procedures have been published previously [14] and 
are detailed in Additional file 1: Supplementary Methods.
In vivo V‑4084 and erlotinib therapeutic efficacy study
All animal studies were approved by the IACUC of Van 
Andel Research Institute. Subcutaneous and orthotopic 
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[14, 16] tumor initiation were performed as previously 
described. The orthotopic tumor growth was measured 
by bioluminescence signal intensity (BLI) using a small 
animal optical imager AMI 1000 (Spectral Instruments 
Imaging, LLC). Dosing with V-4084 and/or erlotinib was 
delivered once daily by oral gavage for 3  weeks. Vehi-
cles used were 0.5 % MC 400 with 0.05 % Tween 80 (for 
V-4084) and with 0.5 % (w/v) methyl cellulose (for erlo-
tinib). To determine the effectiveness of treatment, the 
average tumor size of each group from the last measure-
ment was analyzed with Student’s t test (p < 0.05).
Genomic analysis
From either control or treated animals, tumors were har-
vested for gene expression profiling after 7 days of treat-
ment with V-4084. Total mRNA were extracted using 
miRNeasy minikit (Qiagen, Valencia, CA). Global gene 
expression profiling (GSE64667) was analyzed using 
BRBArrayTools (http://linus.nci.nih.gov/BRB-Array-
Tools.html). To identify the genes that are differentially 
expressed in GBM patients with high or low HGF expres-
sion, the same TCGA data sets (n =  202) was analyzed 
using Student’s t-test (p ≤ 0.00001) under the same cri-
teria as we reported before, considering the top 10 % of 
GBM specimens with the highest HGF expression as 
tumors with HGF-autocrine activation [14]. Genes that 
are differentially expressed in sensitive and insensitive 
xenograft tumor models were analyzed using Student’s 
t-test (p ≤ 0.005). A combined use of human and mouse 
microarrays was performed to identify the genes that 
are differentially expressed in treated tumors (Student’s 
t-test, treated vs. vehicle tumors, p ≤ 0.01). All pathway 
analysis was performed using the Ingenuity Pathway 
Analysis system (IPA, Qiagen). To predict the sensitivity 
to MET inhibitor in PDX models, previously generated 
Agilent gene expression data from 40 patient-derived 
tumor xenograft (PDX) samples were obtained from the 
Gene Expression Omnibus (GSE39242). All further data 
processing and analysis was performed using the Bio-
conductor libraries for the R statistical framework [17]. 
Expression values for the 21 genes associated with the 
tumor sensitivity were isolated from each PDX sample. 
The resulting expression value matrix was organized by 
hierarchical clustering using the heatmap2 function with 
default settings.
Fluorescence in situ hybridization (FISH)
This procedure was performed previously [14] and is 
detailed in Additional file 1: Supplementary Methods.
qPCR
Quantitative real-time PCR was assayed by TaqMan 
Gene Expression Assays (Applied Biosystems, Foster 
City, CA). The -fold difference between insensitive and 
sensitive tumours was calculated using the comparative 
2−ΔΔCt [18].
Immunofluorescence staining
KCI-10-40X1 cells were grown in 6-cm dishes with glass 
bottom and fixed in 4  % paraformaldehyde for 15  min. 
Cells were stained with antibodies as described in Addi-
tional file 1: Supplemental Methods. Imagines were taken 
under Zeiss model 510 confocal microscope.
Results
Selective MET kinase inhibition prevents 
HGF‑autocrine‑mediated GBM invasion
We previously reported that selective MET inhibitors 
may specifically inhibit HGF-autocrine GBM tumor 
growth [14]. Here, we used V-4084, a small molecule 
compound that selectively inhibits MET kinase activity 
(Ki = 0.025 µM; Additional file 1: Table S1), to further test 
inhibition of HGF-autocrine-dependent GBM invasion 
using U87MG malignant glioma cells. Temozolomide 
(TMZ), the standard first-line cytotoxic chemotherapy 
for GBM patients, was used as a reference treatment 
(Fig. 1a). V-4084 significantly inhibited U87MG cell dis-
persal at 3 μM. At the molecular level, V-4084 inhibited 
MAPK signaling at 1  μM or higher concentration, and 
AKT pathway between 1 and 10 μM, suggesting V-4084 
targets invasion-related signaling pathways more strongly 
than proliferation or survival pathways. Another MET 
inhibitor V-837980 showed similar results, completely 
blocking cell dispersal at 3–10 μM. As anticipated, TMZ 
at 50  μM failed to show any anti-migratory activity. 
The efficacy of V-4084 in inhibiting tumor growth was 
tested against orthotopic tumors, in which a firefly lucif-
erase reporter gene was transferred into GBM cells with 
(U87M2) and without (DBM2) endogenous HGF expres-
sion. V-4084 significantly inhibited U87M2 tumor growth 
over 7  days, while DBM2 tumor growth was unaffected 
(Fig. 1c). Consistent with our previous results, the HGF-
autocrine tumor models U87M2 and U118 were sensi-
tive to V-4084 in a dose-dependent manner, while DBM2 
and U251M2 showed no response (Fig.  1d); SF295 cells 
showed modest sensitivity to V-4084. Thus, the U87M2, 
U118, and SF295 malignant glioma cells were determined 
to be models sensitive to MET inhibition, while DBM2 
and U251M2 cells were used as insensitive models for 
further analysis. V-4084 also dose-dependently inhibited 
HGF induced proliferation, urokinase activity, and down-
stream pathway activation (see Additional file 1: Fig. S1).
HGF‑Autocrine GBMs have common genomic profiles
Because HGF-autocrine activation is the key molecular 
feature determining responsiveness to MET inhibitors, 
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we asked whether sensitive glioma subcutaneous xeno-
grafts are transcriptionally similar to each other and 
are dissimilar from insensitive glioma models. We used 
microarrays to test sensitive (U87M2 and U118) and 
insensitive tumors (U251M2 and DBM2) treated for 
7  days with either vehicle or V-4084 (Fig.  1d, n  =  3). 
Unsupervised hierarchical clustering based on a whole-
gene data set (33,304 transcripts, of which 22,372 were 
annotated,  GSE64667) showed that all sensitive tumors 
naturally clustered together and were separated from 
the insensitive ones, indicating common genomic fea-
tures among tumors driven by HGF (Fig.  2a). Look-
ing further at the sensitive tumors (U87M2 and U118), 
we observed that V-4084 treatment did not change the 
expression profiles of the tumors; i.e., all U87M2 tumors 
regardless of treatment clustered together, distinct 
from U118 tumors. Furthermore, treated and untreated 
tumors within each glioma cell line xenograft clustered 
together, suggesting that the constitutive gene expres-
sion in these models was not vulnerable to events driven 
by signaling perturbation upstream (MET inhibition). In 
contrast, clustering pre- and post-treatment of DBM2 
and U251M2 glioma lines was less tight between vehi-
cle and treated tumors indicating that MET inhibition 
had a global effect on gene expression profiles of these 
models (Fig.  2a). Principal Component Analysis (PCA, 
Fig. 2b), which identifies gene expression patterns (prin-
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Fig. 1 V-4084 inhibits HGF-autocrine GBM proliferation and invasion. a By day 3, U87M2 cells had dispersed significantly (top panel). While V-4084 
and its derivative V-837980 significantly inhibited U87MG dispersal at 1 μM, TMZ at 50 μM failed to show any activity. b U87M2 cells constitutively 
show P-MET, P-MAPK, and activate AKT following HGF. V-4084 inhibited HGF-dependent downstream pathways (MET and MAPK) in U87MG dose-
dependently. c To evaluate V4084 efficacy orthotopically, U87M2 cells expressing a luciferase reporter gene (U87M2Luc+) were inoculated into 
nude mice orthotopically, and tumor growth was monitored by BLI twice a week. V4084 at 30 mg/kg significantly inhibited tumor growth ortho-
topically (1 week of dosing, one dose per day; p < 0.05). DBM2 showed no response to V-4084. d V-4084 dose-dependently inhibited HGF-autocrine 
(U87M2, U118, and SF295) subcutaneous tumor growth, but had no effect against tumors without HGF expression (U251M2 and DBM2)
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set, revealed that all sensitive tumors were closer to each 
other and further from the insensitive tumors, regardless 
of V-4084 treatment. The SF295 model showed partial 
sensitivity to V-4084, and its transcriptional profile was 
shown to be intermediate between those of the sensitive 
and insensitive lines (Fig. 2a).
To narrow the roster of genes most associated with 
HGF-autocrine activation in the xenograft studies, we 
analyzed the transcriptional profiles of sensitive (U87M2 
and U118) and insensitive tumors (DBM2 and U251M2) 
without V-4084 treatment and identified 301 genes that 
were differentially expressed between the two groups 
(Fig. 2c; Student’s t test, p ≤ 0.005). While SF295 was not 
included in the initial analysis due to its partial sensitiv-
ity to V-4084, its expression data is included in the heat-
map (Fig.  2c, between the yellow lines). We show that 
sensitive and insensitive tumors were discretely separa-
ble from each other. Moreover, although SF295 statisti-
cally clustered with the sensitive cell lines, it also showed 
similarities to the insensitive lines (Fig.  2c). Among the 
301 genes, the most up-regulated gene was HGF, sup-
porting its role as a driver of the sensitive phenotype. As 
we applied ingenuity pathway analysis (IPA) to depict 
potential pathways populated by the 301 genes, we found 
that “Glioma Invasiveness Signaling” was the third best-
fit pathway based on the differentially-expressed genes 
between sensitive and insensitive glioma cell lines (Addi-
tional file  1: Fig. S2), supporting that HGF-autocrine 
activation is a strong molecular feature that drives GBM 
invasiveness.
A Molecular signature indicating GBM responsiveness 
to MET inhibitors
Our earlier analysis of TCGA data showed that approxi-
mately 30  % of GBMs display overexpression of HGF 
and MET, suggesting instances in the patient popula-
tion where autocrine HGF activation occurs [14]. Using 
the same criteria as we reported previously [14], which 
Fig. 2 GBM models sensitive to V-4084 share common genetic profiles. a Unsupervised hierarchical clustering was performed on tumor samples 
from Fig. 1d; three tumors from each group were used for analysis. Sensitive tumors (U87M2, U118, and SF295SQ1) clustered together, away from 
the insensitive ones (U251M2 and DBM2). Within the most sensitive tumors (U87M2 and U118), there was a clear separation between V4084-treated 
and vehicle-treated samples. b Principal component analysis (PCA) corroborated the results shown in panel A. All sensitive tumors were closer to 
each other and farther from the insensitive tumors. Note that SF295 showed partial sensitivity to V4084 and lies between the two phenotypes. c 
Tumors sensitive and insensitive to V-4084 were analyzed by microarray. We identified 301 differentially expressed genes (Student’s t test, p ≤ 0.005). 
While SF295 was not included in the analysis due to its partial sensitivity, it is in the heatmap between the yellow lines. Although clustering with the 
sensitive cell lines, SF295 tumors share similarities with the insensitive tumors
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posited the top 10 % of GBM specimens with the high-
est HGF expression as tumors with HGF-autocrine 
activation, we contrasted the transcriptional profiles of 
tumors having high and low HGF expression. We found 
887 differentially expressed genes in GBM patients with 
high HGF expression (Student’s t test, p  ≤  0.00001). 
When clustering the 887 genes using the glioma cell 
line xenograft tumor data sets, we observed that   out 
of 887  genes only 56 were able to clearly separate sen-
sitive (U87M2 and U118) and insensitive (DBM2 and 
U251M2) tumors (Fig.  3a, panels A and B). Interest-
ingly, 21 out of 56 (37.5 %) were included in the 301-gene 
profile (Table  1), providing a promising signature that 
may predict whether or not GBM patients will respond 
to MET inhibitors. The most differentially expressed 
genes (TLR4 and CTSZ in Panel A; HGF, AHR, MFAP4, 
and DPT in Panel B, Table 1) were validated by quantita-
tive real-time PCR (qPCR) in xenograft tumors, showing 
concordance to microarray data (Fig. 3b). That all up- or 
down-regulated genes are tightly clustered together in 
their own groups suggests a biological relevance among 
these genes. Our results suggest that the overexpression 
of HGF is associated with a functional network through 






































































































































































































Fig. 3 An HGF signature separates sensitive and insensitive models. a Using the TCGA data sets and approach [14], the transcriptional profiles of 
patients having high or low HGF expression were compared, and 887 genes were identified as differentially expressed (Student’s t test, p ≤ 0.0001). 
After clustering these genes with the glioma cell line xenograft data sets, we found 56 genes that were uniquely down- (Panel A) or up-regulated 
(Panel B) in the sensitive tumors. Among them there are 21 genes overlapping with those found in Fig. 2C, providing a signature of an HGF network 
(Table 1) that may identify tumors sensitive to MET inhibitors. b–c From the 21 gene signature, selected genes that are up-regulated (b) or down-
regulated (c) were validated using qPCR. mRNAs from U87M2 and U118 were used for sensitive tumors, and mRNAs from U251M2 and DBM2 were 
used for insensitive tumors. Fold change = log (signal intensity from sensitive tumors/signal intensity from insensitive tumors)
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The HGF signature identifies sensitivity to MET inhibitors 
in GBM PDX models
To further evaluate the HGF signature’s predictive ability, 
a set of 40 GBM patient-derived xenograft models with 
matched genomic profiles generated by the Ivy GBM 
Consortium (GSE39242) was used for validation analysis. 
Using the 21-gene signature, we clustered the Ivy GBM 
Consortium models according to predicted sensitivity 
to MET inhibition (Fig.  4a). While the models with the 
highest HGF expression level were naturally clustered 
to one end, those with low or no HGF expression lev-
els were clustered to the other end. To validate the sig-
nature’s predictive ability, G116, and G91 which showed 
highest or no HGF expression levels (Fig. 4c) were tested 
for sensitivity to V-4084, erlotinib and the combination 
of the two (Fig. 4b). We found that G116 was highly sen-
sitive to V-4084 alone, but erlotinib had no effect, while 
G91 showed exactly the opposite. These results suggest 
a mutually exclusive effect by the two RTKs and support 
the previous finding that MET negatively correlates with 
EGFR expression in primary GBM.
Host‑tumor interaction in response to MET kinase inhibitor
Although it is well accepted that the host’s microenviron-
ment regulates tumor growth, genomic approaches have 
not been used to dissect host/tumor cross talk or to delve 
into ways targeted therapy alters the host (non-tumor) 
cells. To explore this, we combined the use of human and 
mouse microarrays to study gene expression changes in 
tumor cells and host cells in response to MET inhibitors. 
mRNA samples from pre- and post-treatment tumors 
were used in transcriptional profile analysis on both 
human and mouse microarrays. The molecular pathway 
data from the human microarray portrays the tumor 
response to V-4084 treatment (Additional file 1: Fig. S3), 
and the data from the mouse microarray represent the 
microenvironmental response (Additional file 1: Fig. S4). 
From the human array data sets, we identified 485 genes 
that were differentially expressed in treated tumors (Stu-
dent’s t test, treated vs. vehicle, p ≤ 0.01). A supervised 
cluster based on the 485 genes showed a clear separa-
tion between treated and vehicle samples only in U87M2 
and U118 tumors, which have HGF-autocrine activation 
Table 1 The HGF signature genes
By analyzing the mRNA expression datasets from TCGA GBM patients and those from preclinical xenograft models, 21 genes were found uniquely down- or 
up-regulated only in the sensitive tumors, providing a signature of an HGF network to identify tumors sensitive to MET inhibitors
a Ratio = average mRNA expression level in insensitive tumors/average mRNA expression level in sensitive tumors
GeneSymbol GeneName Ratioa P value Chromosome
From panel A: genes that are down-regulated only in sensitive tumors (n = 9)
 GPLD1 Glycosylphosphatidylinositol specific phospholipase D1 0.48 0.0019391 14
 NOVA2 Neuro-oncological ventral antigen 2 0.46 0.0026136 7
 LRP5 Low density lipoprotein receptor-related protein 5 0.41 0.0028902 11
 ARHGEF4 Rho guanine nucleotide exchange factor (GEF) 4 0.35 0.0013269 2
 F11R F11 receptor 0.33 0.0005396 1
 ALDH5A1 Aldehyde dehydrogenase 5 family, member A1 0.31 0.0003027 6
 SLIT3 Slit homolog 3 (Drosophila) 0.22 0.000271 11
 TLR4 Toll-like receptor 4 0.088 2.59E−05 9
 CTSZ Cathepsin Z 0.081 0.0044628 20
From panel B: genes that are up-regulated only in sensitive tumors (n = 12)
 HGF Hepatocyte growth factor (hepapoietin A; scatter factor) 47.52 0.000534 7
 AHR Aryl hydrocarbon receptor 46.56 2.35E−05 7
 MFAP4 Microfibrillar-associated protein 4 28.51 8.53E−05 17
 DPT Diptericin 9.37 0.0027492 2R
 COL3A1 Collagen, type III, alpha 1 8.210 0.0012553 2
 F2RL2 Coagulation factor II (thrombin) receptor-like 2 3.96 0.003144 5
 LPXN Leupaxin 3.86 0.0038993 11
 DAB2 Dab, mitogen-responsive phosphoprotein, homolog 2 3.5 0.0035502 5
 TBC1D8B TBC1 domain family, member 8B (with GRAM domain) 2.7 0.0015932 X
 GPHN Gephyrin 2.63 0.0038916 6
 C16orf45 Chromosome 16 open reading frame 45 1.99 0.0048897 16
 CREB3L2 cAMP responsive element binding protein 3-like 2 1.87 0.0047229 7
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(Additional file  1: Fig. S3A, B). In contrast, none of the 
insensitive tumors showed clear separation, consistent 
with treatment having little effect (Additional file 1: Fig. 
S3A). To plot the most significant genes (n =  550, Stu-
dent’s t test, treated vs. vehicle, p ≤  0.01) and signaling 
pathways affected by V-4084 treatment, we performed 
the same analysis using only the two most sensitive 
tumor models, U87M2 and U118, and found that the 10 
most affected signaling pathways were almost all asso-
ciated with cell cycle regulation (Additional file  1: Fig. 
S3C), which is consistent with other groups’ reports that 
the MET kinase inhibitor SGX523 impedes cancer cell 
proliferation and cell cycle progression [19, 20].
In order to study the host response to MET kinase 
inhibitors, the same mRNA samples used for the 
human microarray were analyzed by Affymetrix mouse 
microarrays. Consistent with the observation from the 
human array (Fig.  3a), unsupervised clustering and 
PCA analysis performed on the whole mouse gene data 
set (n =  25,255 transcripts) showed a clear separation 
between sensitive and insensitive tumors (Additional 
file 1: Fig. S4A, B). Analyzing treated vs. vehicle tumors 
using mouse data sets for only U87M2 and U118 tumors 
revealed 370 genes that were differentially expressed 
(Student’s t test, p ≤ 0.01). Interestingly, the most highly 
altered signaling pathway in the host (Cell cycle: G2/M 
DNA Damage Checkpoint regulation) turned out to be 
cell-cycle-regulation related. Altogether, four pathways 
(Mitotic Roles of Polo-Like Kinase; ATM Signaling; 
Cell Cycle: G2/M DNA Damage Checkpoint Regula-
tion; and Estrogen-Mediated S-Phase Entry) were the 
same as from the human array results which indicate 
the response from the tumor side (Additional file 1: Fig. 
S3C). To eliminate the possibility that a pathway iden-
tified from both human and mouse arrays might come 
from the overlapping design of the array probes, we 
carefully compared the differentially expressed genes 
from both arrays and found no redundancies (Addi-
tional file  1: Fig. S4E). Our data suggest that although 
MET inhibitors have consequences on distinct molecu-
lar processes on subcutaneous glioma tumor cells and 
host cells within the tumor (endothelial cells, mac-
rophages, stromal elements, etc.), V-4084 affects cell 
cycle in both tumor and host.
MET activation in EGFRamp GBM resistant to Erlotinib
Although EGFRamp occurs in about 45  % of GBM 
patients, clinical trials using EGFR inhibitors failed to 
show activity. To test whether MET pathway activation 
may serve as a bypass mechanism, [8] we established a 
patient-derived EGFRamp GBM model (KCI-10-40) with 
acquired resistance to erlotinib, then measured its sensi-
tivity to MET inhibitor (Fig. 5). While 29.5 % of the cells 
in the primary tumor carry EGFRamp (Fig. 5A, a, b), iso-
lated neurosphere cells showed 100 % EGFRamp (Fig. 5A, 
c, d). These cells express nestin, vimentin, and SOX2 
(Fig.  5B) and show malignant orthotopic tumor growth 
(Fig.  5A, e, f), indicating that EGFRamp is serially-main-
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Fig. 4 HGF signature ranks the predicted sensitivity of GBM-PDX 
models to MET inhibitors. a Forty GBM patient-derived tumor models 
were analyzed by using the HGF signature as a biomarker of suitabil-
ity for treatment with MET inhibitors. Models with high HGF expres-
sion are clustered together at right side of the heatmap, suggesting 
a common molecular profile and a high sensitivity to MET-targeted 
therapy. b GBM models G116 and G91 were used to validate the 
therapeutic efficacy of V-4084. G116, ranked the most sensitive to 
MET inhibitor, showed significant response to V-4084 treatment; G91, 
ranked the insensitive, showed no response. c HGF, MET, and EGFR 
mRNA expression levels in G116 and G91 tumor models
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To induce acquired resistance, KCI-10-40X1cells were 
inoculated into nude mice subcutaneously followed by 
continuous erlotinib treatment (75–100  mg/kg). While 
significant tumor regression was observed in the first 
week (Fig. 5C), tumors started to re-grow after 5 weeks 
of continuous treatment, with progressively increasing 
growth rate, consistent with the manifestation of a rescue 
pathway independent of EGFR. The same transplant pro-
cedure was serially repeated four times to establish the 
tumor model adaptive to erlotinib treatment (KCI-10-
40X1/erl). In vivo, simply switching treatment from erlo-
tinib to V-4084 did not inhibit tumor growth (Fig. 5D). A 
combination of V-4084 and erlotinib, however, retarded 
KCI-10-40X1/erl tumor growth (Fig.  5E). Concordant 
with our previous results demonstrating that inhibi-
tion of the MET pathway in U87 tumors result in EGFR 
pathway activation [14], this study support a biological 
reciprocity between the two pathways and provides addi-
tional evidence for the combined use of MET and EGFR 
inhibitors in treating GBM patients with EGFRamp.
Discussion
Standard-of-care for treating GBM involves maximum 
surgical resection followed by the Stupp regimen con-
sisting of fractionated radiotherapy plus concurrent 
daily chemotherapy using the alkylating agent TMZ, 
and 6-12 cycles of adjuvant TMZ [21]. However, in 
spite of this aggressive multimodal approach, local inva-
sion and tumor recurrence is seen in nearly all patients 
and is largely due to the highly infiltrative and adaptive 
GBM cells [22]; and, overall, the median patient survival 
remains a dismal at less  than 15  months with a 5-year 
survival rate less than 5 %. As such, there has been con-
siderable interest in recent years in applying a targeted 
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Fig. 5 Therapeutic efficacy of MET and EGFR inhibitors using the KCI-10-40 PDX model. A Characterization of the KCI-10-40X1 PDX model. KCI-10-
40 primary GBM showed 29.5 % EGFR amplification (a, b). After the primary tumor was grown as a xenograft, neurosphere cells were derived for 
in vitro growth (c) which showed 100 % EGFR amplification (d). These cells induce intracranial tumor growth in the mouse brain (e and f). B KCI-10-
40X1 cells express nestin, vimentin, and Sox2, as shown by immunofluorescence staining, indicating stem-cell-like properties. C KCI-10-40X1 tumors 
showed high sensitivity to erlotinib treatment (75 mg/kg); tumor regression could be seen after 1 week. However, after 5 weeks of continuous treat-
ment at 100 mg/kg, tumors began to regrow much faster, indicating the start of acquired resistance. Note that KCI-10-40X1 took 2 weeks to reach 
1000 mm3 in size, while the resistant tumor (KCI-10-40X1/erl) took almost 11 weeks to reach similar size. D Although KCI-10-40X1/erl tumors grow 
while on erlotinib treatment, discontinuing treatment (vehicle) accelerated tumor growth. V-4084 (100 mg/kg) alone did not inhibit KCI-10-40X1/erl 
tumor growth. E V-4084 (100 mg/kg) in combination with erlotinib (100 mg/kg) inhibited KCI-10-40X1/erl tumor growth
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approach to GBM patients. The success of targeted 
therapies depends on both knowledge of the essential 
molecular features that drive pathway activity and proper 
selection of the patient population likely to respond 
favorably to the specific treatment. Examples of such suc-
cesses include the use of EGFRT790M as a marker for erlo-
tinib treatment of non-small-cell lung cancer (NSCLC) 
patients [23] and use of BRAFV600E for vemurafenib treat-
ment of melanoma patients [24]. Our prior studies have 
shown that MET inhibitors can effectively impair HGF-
autocrine GBM tumor growth [14, 25]. In this study, we 
further demonstrated that HGF-autocrine-driven GBM 
invasion can be significantly blocked by MET inhibitors 
(Fig. 1); these findings support the use of HGF-autocrine 
activation as a biomarker for identifying GBM patients 
most likely to benefit from treatment with MET inhibi-
tors. This result raises the prospect for a potential clini-
cal application in GBM patients with HGF-autocrine 
activation, where use of MET inhibitors before surgical 
resection may target the invasive tumor cells at the lead-
ing edge and help to better define the tumor margin and 
facilitate maximal surgical removal. Likewise, treating 
GBM patients with MET inhibitors after surgical debulk-
ing may enhance the efficacy of adjuvant radiation and 
chemotherapy by arresting the invading glioma cells.
Despite the large collection of primary tumor data sets 
that TCGA has generated, this profiling data proves of 
limited direct use when the aim is to discover predictive 
signatures for response to specific treatments. Presently, 
very few patients enrolled in clinical trials of targeted 
therapeutics undergo systematic profiling of their GBM 
tissue in an attempt to align unique genomic signatures 
with response to the targeted drug. Advancement of new 
targeted agents, i.e., chemical probes, could be facilitated 
by more parallel study of panels of relevant preclini-
cal models that are genomically profiled. To date, only 
hypermethylation of the O6-methylguanine-DNA-meth-
yltransferase (MGMT) gene, which has been shown to 
be a predictive marker of sensitivity to alkylating agents 
(such as TMZ) and associated with improved outcome, 
has been routinely employed in a clinical setting as a 
predictive signature in GBM patients [13]. In contrast, 
therapeutic efficacy using xenograft models is easy to 
determine, however, concerns remain regarding how 
closely xenograft models resemble human cancer biology.
In this study, we developed a two-step strategy to iden-
tify tumors that are sensitive to MET-inhibiting drugs 
and to identify the genes that were highly associated 
with HGF overexpression and that were up- or down-
regulated coincident to MET-inhibition response. We 
first conducted a training analysis with TCGA data sets 
to identify up- or down-regulated genes in GBM tumors 
which overexpressed HGF. A data mingling using TCGA 
human data together with analysis of the xenograft data-
base eliminated the “non-human” factors from the xeno-
graft model data sets. Although 887 and 301 genes were 
differentially expressed in the human and xenograft 
data sets, a subset of 21 genes was able to clearly sepa-
rate responders from nonresponders, demonstrating the 
value of using human data sets to help inform the results 
from xenograft studies. In the next step, a data set inde-
pendently derived from GBM PDX orthotopic models 
was used for validation of predictive therapeutic efficacy. 
The heatmap showed a cluster of models highly corre-
lated to HGF expression, but it also showed that other 
components were involved in determining vulnerability 
to MET inhibition. The 21-gene signature may represent 
a functional HGF network, although a biological infer-
ence towards a hallmark or a phenotype requires further 
study. Most importantly, after therapeutic validation, the 
prediction of G116 as a responder and G91 as a non-
responder was accurate (Fig. 4), highlighting the potential 
of this signature for enrolling patients in MET-targeted 
therapy. Although extensive validation (i.e., through 
repeating step two) is needed to optimize the molecular 
signature for clinical purposes, our study is a “proof-of-
concept” that combining TCGA primary tumor datasets 
(human) and xenograft tumor model datasets (human 
tumor grown in mice) using therapeutic efficacy as an 
endpoint may serve as a useful approach to discover and 
develop molecular signatures as therapeutic biomarkers 
for targeted therapy.
Although genomic and proteomic tools have been 
widely used to analyze GBM subtypes [5, 6], to map out 
specific mutations and signaling pathways [4], or to iden-
tify therapeutic targets related in particular to MET and 
EGFRvIII in combination [11], these approaches have not 
been used to interpret micro-environmental regulation. 
The result of using human and mouse arrays to iden-
tify the core pathways affected by MET inhibitors in the 
context of tumor/host crosstalk is speculative but very 
promising. Although the use of human xenograft tumor 
models can be debated due to the loss of human host 
cell biology, in our study, the use of specific human and 
mouse arrays allows us to measure the signaling path-
ways impacted in the host and tumor compartments, by 
which the biological response from host and tumor can 
be viewed independently. As we have shown, the genes 
differentially expressed from the human array (n = 550) 
are very different from those in the mouse array 
(n  =  370), with no overlapping genes. Although nude 
mice are claimed not to have an intact immune system, 
we observed pathways such as host-versus-graft disease 
signaling and antigen presentation to be up-regulated 
in sensitive xenografts, indicating an increased immune 
reaction in the host that might be required for treatment 
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efficacy [26]. On the tumor side, all pathways identified 
were associated with cell-cycle regulation. Strikingly, 
non-overlapping genes from the tumor and the host still 
yielded overlapping pathways, with cell-cycle regulation 
as the common process. Our study, then, uses xenograft 
mouse models plus human and mouse arrays to provide 
preliminary, yet important, information about the tumor/
host interaction in response to MET inhibitors. Although 
a more clinically-relevant analysis of tumor/host cross-
talk requires the use of orthotopic models, we suggest 
that for GBM patients in clinical trials, the immune reac-
tions of individual patients might help identify vulner-
ability to MET inhibitors.
A number of RTK inhibitors have entered cancer clini-
cal trials with limited efficacy; one of the major obsta-
cles noted has been the rapid development of acquired 
resistance to the targeted drug [27, 28]. MET pathway 
activation has been frequently reported as a mechanism 
of tumor recurrence in NSCLC (EGFRT790M) treated 
with erlotinib [23, 29], in melanoma (BRAFV600E) treated 
with vemurafenib [24], and in GBM treated with beva-
zicumab [30]. Preclinically, MET inhibitors have been 
used to induce resistance via different mechanisms in 
different cancer types [31]. While findings repeatedly 
emphasize the importance of targeting the MET pathway 
in primary and recurrent cancer, the strategies are shift-
ing from monotherapy to multi-target therapy. Although 
EGFRamp is one of the most common genetic alterations 
in GBM and is often accompanied by constitutively ele-
vated p-EGFR, clinical trials using EGFR inhibitors such 
as erlotinib or gefitinib have invariably failed to provide 
clinically meaningful benefit to patients harboring a 
GBM. The mechanisms leading to such failures include 
dynamic regulation of extrachromosomal mutant EGFR 
DNA [32], up-regulation of PI3Kp110δ [33], and depres-
sion of PDGFRβ transcription [34]. Previously, we 
observed that expression of MET correlated negatively 
with EGFR and that long-term exposure to MET inhibi-
tors in the U87MG model induced resistance via the 
EGFR pathway. This observation indicated an intrinsic 
balance between MET and EGFR, i.e., inhibiting one may 
activate the other. Here, we further tested whether inhib-
iting EGFR causes MET activation as a rescue pathway 
and whether a combination of the two RTK inhibitors 
would improve the efficacy in treating EGFRamp GBM 
that escape erlotinib treatment. By using KCI-10-40X1, a 
PDX model derived from a GBM patient with EGFRamp, 
we found that a combination of V-4084 and erlotinib 
inhibited KCI-10-X1/erl-res tumor growth and provide 
additional evidence to treat GBM EGFRamp patients tar-
geting both EGFR and MET. The mechanisms underlying 
how the MET-EGFR interaction controls drug sensitivity 
require further study.
Conclusion
In summary, specific MET inhibitors block HGF-auto-
crine-dependent GBM proliferation and invasion. Using 
HGF-autocrine activation as a biomarker, we developed a 
molecular signature that may be used to predict sensitiv-
ity to MET inhibitors. The MET inhibitors regulate tumor 
and host crosstalk, and overall impede tumor growth by 
inhibiting cell cycle progression. We also suggest that 
long-term exposure of EGFRamp GBM to erlotinib treat-
ment may initiate MET pathway activation, further sup-
porting the earlier use of MET and EGFR inhibitors in 
combination for treating malignant GBM.
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